Daniel Alfaro, MD
Ophthalmology · Charleston, SCNPI 1982719290
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), other and ownership interests — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by US Retina LLC at 46.9% of the total. Reporting peaked in 2022 at $6,832 and has fallen 83.7% since, to $1,116 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $51.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$7K
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$951
- Genentech USA, Inc.$945
- Alimera Sciences, Inc.$617
- Abbott$449
- plus $4K from 27 others
Across 1,440 payments — averaging $3187.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.5M
- Regeneron$1.1M
- Bayer$690K
- Roche TCRC, Inc.$316K
- Kyowa Kirin, Inc.$239K
- Novartis$192K
- plus $585K from 11 others
What the payments were for
- Travel & lodging$4493%
- Food & beverage$7,29749%
- Education$1041%
- Entertainment$1201%
- Ownership interest$2,88919%
- Other$4,15728%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $7,046 |
| Regeneron Healthcare Solutions, Inc. | 36 | $1,079 |
| AbbVie(2 entities) | 41 | $951 |
| Genentech USA, Inc. | 50 | $945 |
| Alimera Sciences, Inc. | 30 | $617 |
| Abbott | 2 | $449 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $426 |
| Eyepoint US, Inc. | 5 | $328 |
| Novartis | 5 | $293 |
| Astellas Pharma US Inc | 12 | $273 |
| Biogen | 12 | $253 |
| Harrow Eye, LLC | 12 | $250 |
| Coherus Oncology, Inc. | 4 | $230 |
| Apellis Pharmaceuticals, Inc. | 2 | $192 |
| Kala Pharmaceuticals, Inc. | 15 | $187 |
| Neurotech Pharmaceuticals, Inc. | 1 | $172 |
| Mallinckrodt Hospital Products Inc. | 4 | $169 |
| Ocular Therapeutix, Inc. | 3 | $155 |
| Optos, Inc. | 2 | $140 |
| Alcon | 1 | $124 |
| Dutch Ophthalmic, USA | 4 | $117 |
| Genentech, Inc. | 1 | $112 |
| Aerie Pharmaceuticals, Inc. | 1 | $112 |
| Carl Zeiss Meditec, Inc. | 2 | $85 |
| Bausch & Lomb Americas Inc. | 4 | $70 |
| Omeros Corporation | 4 | $49 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Notal Vision, Inc. | 1 | $33 |
| Amgen(2 entities) | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Travere Therapeutics, Inc. | 6 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,016 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobradex StTobramycin/Dexamethasone | 16 | $3,689 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $3,298 |
| Prednisolone Acetate | 113 | $2,944 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $2,062 |
| Bromfenac Sodium | 13 | $1,757 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 42 | $1,615 |
| Loteprednol Etabonate | 11 | $1,450 |
| Latanoprost | 39 | $395 |
| Timolol Maleate | 12 | $139 |
| Tobramycin | 16 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eyevance Pharmaceuticals LLCTobradex St | $20 | $3,68916 claims |
| AbbVieCombigan | $951 | $3,29812 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $426 | $1,45011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Charleston
- Karolinne RochaCharleston$552K
- Drew DicksonCharleston$53K
- Mona CamacciCharleston$26K
- Cole MillikenCharleston$17K
- Karen FernandezCharleston$13K
- John KerrisonCharleston$12K
- Eric JablonCharleston$12K
- Marion WilsonCharleston$9K
- Michael JohnsonCharleston$9K
- Berdine BurgerCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.